Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI

Status Recruiting

Clinical Trial Summary

Therapeutic agents used in malignant melanoma treatment such as BRAF/MEK inhibitors and anti-CTLA-4/Anti-PD-1 antibodies go along with harmful side effects in a considerable proportion of patients and treatment costs may cause relevant medical expenditures per month. Currently, therapy response assessment in melanoma patients is performed using RECIST criteria which are based on changes in tumour size. PET/CT combines morphological and metabolic information. Thus, the so-called PERCIST-criteria were introduced integrating change in size and glucose utilization for response assessment in solid tumors. Due to the different mechanism of action these new agents introduce different response patterns increase in tumor size due to inflammation for antibody therapies). In conventional chemotherapies, re-staging is usually performed 3 months after treatment initiation which is the result of empirical investigations. Moreover, it has recently been shown, that response to new targeted therapies can be detected much earlier using PET or functional MR techniques. This forms the rationale for the monitoring of melanoma patients using a combined PET/MR technique after only 2 weeks of therapy initiation. Especially for patients in stage IV with a medium survival time of 12 months, a 2.5 months earlier re-staging and therapy adjustment would have significant consequences for the individual clinical course.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03132090
Study type	Interventional
Source	University Hospital Tuebingen
Contact	Nina Schwenzer, MD
Phone	+49 7071 29-87720
Email	nina.schwenzer@uni-tuebingen.de
Status	Recruiting
Phase	N/A
Start date	September 29, 2014
Completion date	June 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01676779` - mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma	Phase 2
Terminated	`NCT04577729` - The IRMI-FMT Trial	N/A
Completed	`NCT02439411` - Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
Completed	`NCT00313235` - Combined Modality Treatment for Patients With Stage IV Melanoma	Phase 1/Phase 2
Recruiting	`NCT03166397` - Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients	Phase 2
Not yet recruiting	`NCT05304546` - Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma	Phase 2
Terminated	`NCT00722098` - Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients	Phase 2
Terminated	`NCT03430947` - Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases	Phase 2
Completed	`NCT01189383` - IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma	Phase 1/Phase 2
Completed	`NCT01983124` - Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib	Phase 2
Completed	`NCT01302496` - Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma	Phase 2
Not yet recruiting	`NCT03493230` - Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )	N/A